Top Page
Aurora Cannabis
(NASDAQ:ACB)
Aurora Cannabis (ACB) vs. iShares MSCI Canada ETF (EWC)
Aurora Cannabis Business Overview & Revenue Model
Aurora Cannabis Earnings Call Summary
Aurora Cannabis Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 357.88M | 343.29M | 270.28M | 233.29M | 221.34M | 245.25M |
| Gross Profit | 140.64M | 187.61M | 131.46M | -64.36M | 21.23M | -21.56M |
| EBITDA | 24.75M | 51.35M | -12.34M | -210.74M | -1.55B | -535.28M |
| Net Income | -20.14M | 1.59M | -69.33M | -265.33M | -1.72B | -693.63M |
Balance Sheet | ||||||
| Total Assets | 837.84M | 852.67M | 838.67M | 926.32M | 1.08B | 2.60B |
| Cash, Cash Equivalents and Short-Term Investments | 186.03M | 138.47M | 117.47M | 300.84M | 439.14M | 425.21M |
| Total Debt | 101.63M | 104.58M | 104.79M | 227.52M | 269.49M | 399.55M |
| Total Liabilities | 249.16M | 244.07M | 236.80M | 409.19M | 422.00M | 567.03M |
| Stockholders Equity | 551.92M | 567.17M | 559.77M | 486.08M | 661.84M | 2.04B |
Cash Flow | ||||||
| Free Cash Flow | -999.00K | -2.85M | -85.46M | -127.95M | -142.48M | -263.66M |
| Operating Cash Flow | 17.75M | 16.00M | -68.51M | -115.82M | -110.27M | -210.58M |
| Investing Cash Flow | -20.18M | -14.33M | -5.49M | -27.29M | -36.17M | -26.91M |
| Financing Cash Flow | 3.77M | -116.00K | -47.92M | -56.48M | 147.78M | 521.95M |
Aurora Cannabis Technical Analysis
Aurora Cannabis Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$1.33B | 51.18 | 1.73% | ― | 31.72% | ― | |
59 Neutral | C$294.17M | 70.00 | 1.86% | ― | 38.86% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.39B | ― | -85.59% | ― | 2.31% | -726.17% | |
49 Neutral | $478.76M | ― | -7.82% | ― | 1.76% | 18.31% | |
47 Neutral | C$362.43M | ― | -10.76% | ― | 23.87% | -19.57% | |
40 Underperform | C$588.17M | ― | -98.42% | ― | -4.24% | 55.82% |
Aurora Cannabis Corporate Events
Aurora Cannabis Inc. released its interim financial statements for the three and six months ended September 30, 2025, showing a notable increase in revenue compared to the previous year. The company’s financial position reflects a decrease in total assets and liabilities, with a slight decline in shareholders’ equity, indicating ongoing financial adjustments and strategic positioning in the competitive cannabis market.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$7.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis reported its fiscal 2026 second quarter results, showcasing a 15% year-over-year increase in global medical cannabis net revenue to a record $70.5 million and a 22% rise in international medical cannabis revenue to $42.7 million. The company achieved a 52% growth in adjusted EBITDA, reaching $15.4 million, and maintained a strong balance sheet with $141.9 million in cash and a debt-free cannabis business. Despite a decrease in consumer cannabis revenue, Aurora’s strategic focus on high-margin medical cannabis markets and operational efficiencies contributed to improved gross margins and profitability, positioning the company for continued growth.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$7.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis announced it will host a conference call to discuss its second quarter 2026 financial results on November 5, 2025. The call will be led by the company’s executive chairman and CEO, Miguel Martin, and CFO, Simona King. This announcement is part of Aurora’s ongoing efforts to maintain transparency with investors and stakeholders, reflecting its commitment to providing timely updates on its financial performance.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$9.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis Inc. has announced a significant investment in its EU-GMP manufacturing facility in Leuna, Germany, aimed at enhancing operational capabilities over the next five years. This investment will increase flower growth capacity, improve product quality, and drive cost efficiency, positioning Aurora to meet the growing demand for high-quality medical cannabis in Europe. The upgrades will include additional grow rooms and new irrigation and lighting systems, strengthening Aurora’s supply chain resilience and expanding its domestic capabilities in EU-GMP certified manufacturing.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$7.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis Inc. announced the results of its 2025 Annual General and Special Meeting, where shareholders voted on various resolutions, including the election of directors and the appointment of auditors. Theresa Firestone resigned from the Board of Directors, and Michael Singer was appointed as the new Lead Independent Director and Chair of the Human Resources and Compensation Committee. The meeting also saw the approval of amendments to the company’s RSU Plan, PSU Plan, and Share Option Plan, although the advisory vote on executive compensation did not pass.
The most recent analyst rating on (TSE:ACB) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis Inc., a prominent player in the global medical cannabis industry, is headquartered in Edmonton, Alberta, and operates across Canada, Europe, Australia, and New Zealand, offering a diverse range of cannabis products for both medical and consumer markets.
Aurora Cannabis Reports Strong Earnings Amid Challenges
Aurora Cannabis announced its fiscal first quarter 2026 results, highlighting a 37% increase in global medical cannabis net revenue to $64.8 million, with international revenue growing by 85%. The company achieved a 209% growth in adjusted EBITDA to $10.8 million and generated positive free cash flow of $9.2 million. Despite a decrease in consumer cannabis revenue, Aurora maintained a strong balance sheet with $186 million in cash and a debt-free cannabis business. The results underscore Aurora’s strategic focus on high-margin medical cannabis markets, particularly in Europe, and the continued expansion of its plant propagation business.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Aurora Cannabis Inc. has released its interim financial statements for the three months ended June 30, 2025, showing a net revenue increase to $98.023 million from $83.435 million in the same period in 2024. This financial update indicates a positive trend in the company’s revenue, which could enhance its market position and stakeholder confidence.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.